Glaxosmithkline | GSK - Pre Utilidad Fiscal





Pre Utilidad Fiscal Cambio Fecha
AbbVie USD 5.57B 2.9B 2026-03
Amgen USD 1.51B 2.41B 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
Aurora Cannabis CAD 11.41M 12.99M 2026-03
Bausch Health Companies USD 56M 162M 2025-12
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Canopy Growth CAD -157.96M 95.71M 2026-03
Corcept Therapeutics USD 9.91M 5.33M 2025-12
Drreddys Laboratories INR 2B 13.43B 2026-03
Eli Lilly USD 8.27B 1.03B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Glaxosmithkline GBP 2.14B 312M 2026-03
J&J USD 8.66B 839M 2026-06
Merck USD 3.42B 3.32B 2025-12
Novartis USD 3.84B 802M 2026-03
Pacira USD 571K 8.95M 2025-12
Perrigo USD -1.33B 1.35B 2025-12
Pfizer USD 5.18B 6.82B 2026-03
Phibro Animal Health USD 38.62M 1.26M 2025-12
Prestige Brands USD 61.81M 7.32M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sanofi EUR -1.16B 5.5B 2025-12
Supernus Pharmaceuticals USD -5.95M 4.04M 2026-03
Takeda JPY -52.48B 186.34B 2026-03
Teva Pharmaceutical Industries USD 753M 662M 2026-03
Zoetis USD 761M 126M 2025-12